Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Shire Phase II Study of MDD Adjunctive Therapy Vyvanse Capsules Meets Endpoints
Dec. 9, 2011
Shire reported results from a Phase II trial of its adjunctive therapy Vyvanse capsules for patients suffering from major depressive disorder with the change in global executive composite T-score of the behavioral rating inventory of executive function - adult version assessment being the primary efficacy measure.
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing